Circulating tumor DNA (ctDNA)—genetic material shed from tumors into the bloodstream—may help risk-stratify patients with Stage 3 colon cancer by tailoring chemotherapy options after surgery based on risk of cancer recurrence, according to new research co-led by investigators at the Johns Hopkins Kimmel Cancer Center.
Continue Reading this article here
